Novo Nordisk, Fujifilm Cellular Dynamics partner for iPSC-derived cell therapies
Novo Nordisk will obtain the right to use Fujifilm Cellular Dynamics’ iPSC platform for research and development and…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
06 Jan 23
Novo Nordisk will obtain the right to use Fujifilm Cellular Dynamics’ iPSC platform for research and development and…
06 Jan 23
The FDA designation for the 24-valent PCV vaccine candidate was based on positive topline data results from a…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
05 Jan 23
The acquisition is expected to support Moderna’s suite of platform technologies, and OriCiro’s synthetic biology and enzyme technologies…
05 Jan 23
The Chinese CRDMO will grant GSK a licence for one preclinical bi-specific T cell engaging antibody and the…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Jan 23
Gilead will obtain an option to licence EVOQ’s nanodisc technology and exclusive rights to develop and commercialise immunotherapy…
03 Jan 23
Sandoz will acquire the global rights to ALT-B4, derived using Alteogen’s Hybrozyme technology, to develop a subcutaneous version…
02 Jan 23
The Phase 3 study has met its primary endpoint of non-inferiority and superiority in the annualised bleeding rate…
29 Dec 22
As per the deal, PeptiDream will offer peptide candidates found from PeptiDream’s Peptide Discovery Platform System technology for…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Dec 22
Actemra is a humanised monoclonal antibody indicated for hospitalised adult patients receiving systemic corticosteroids and require supplemental oxygen,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates